Incannex Healthcare Ltd ADR (IXHL) - Net Assets
Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has net assets worth $75.23 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($80.28 Million) and total liabilities ($5.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Incannex Healthcare Ltd ADR tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $75.23 Million |
| % of Total Assets | 93.71% |
| Annual Growth Rate | 12.87% |
| 5-Year Change | 107.85% |
| 10-Year Change | N/A |
| Growth Volatility | 175.69 |
Incannex Healthcare Ltd ADR - Net Assets Trend (2006–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Incannex Healthcare Ltd ADR to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Incannex Healthcare Ltd ADR (2006–2025)
The table below shows the annual net assets of Incannex Healthcare Ltd ADR from 2006 to 2025. For live valuation and market cap data, see market value of Incannex Healthcare Ltd ADR.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $13.39 Million | +19.36% |
| 2024-06-30 | $11.22 Million | -64.21% |
| 2023-06-30 | $31.34 Million | -12.92% |
| 2022-06-30 | $36.00 Million | +458.79% |
| 2021-06-30 | $6.44 Million | +196.26% |
| 2020-06-30 | $2.17 Million | +619.06% |
| 2019-06-30 | $-418.90K | -8.72% |
| 2018-06-30 | $-385.29K | -127.38% |
| 2017-06-30 | $-169.45K | +75.81% |
| 2016-06-30 | $-700.36K | -246.37% |
| 2015-06-30 | $478.47K | -72.50% |
| 2014-06-30 | $1.74 Million | -87.16% |
| 2013-06-30 | $13.55 Million | -32.60% |
| 2012-06-30 | $20.10 Million | +31.96% |
| 2011-06-30 | $15.23 Million | +23.94% |
| 2010-06-30 | $12.29 Million | +86.81% |
| 2009-06-30 | $6.58 Million | -30.81% |
| 2008-06-30 | $9.51 Million | +43.11% |
| 2007-06-30 | $6.64 Million | +395.31% |
| 2006-06-30 | $1.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Incannex Healthcare Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15669258700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | 0.15% |
| Other Comprehensive Income | $-3.12 Million | -23.33% |
| Other Components | $174.05 Million | 1299.94% |
| Total Equity | $13.39 Million | 100.00% |
Incannex Healthcare Ltd ADR Competitors by Market Cap
The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
$38.02 Million |
|
Siyata Mobile Inc
NASDAQ:SYTA
|
$38.03 Million |
|
Summa Silver Corp
V:SSVR
|
$38.04 Million |
|
GBK Beteiligungen AG
HM:GBQ
|
$38.04 Million |
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
$38.01 Million |
|
Red Metal Ltd
AU:RDM
|
$37.99 Million |
|
Lii Hen Industries Bhd
KLSE:7089
|
$37.96 Million |
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
$37.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Incannex Healthcare Ltd ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,217,000 to 13,389,000, a change of 2,172,000 (19.4%).
- Net loss of 46,885,000 reduced equity.
- Other comprehensive income increased equity by 208,000.
- Other factors increased equity by 48,849,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.88 Million | -350.18% |
| Other Comprehensive Income | $208.00K | +1.55% |
| Other Changes | $48.85 Million | +364.84% |
| Total Change | $- | 19.36% |
Book Value vs Market Value Analysis
This analysis compares Incannex Healthcare Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | $83.66 | $3.79 | x |
| 2007-06-30 | $269.73 | $3.79 | x |
| 2008-06-30 | $212.09 | $3.79 | x |
| 2009-06-30 | $119.32 | $3.79 | x |
| 2010-06-30 | $84.29 | $3.79 | x |
| 2011-06-30 | $77.66 | $3.79 | x |
| 2012-06-30 | $7.47 | $3.79 | x |
| 2013-06-30 | $3.35 | $3.79 | x |
| 2014-06-30 | $5.12 | $3.79 | x |
| 2015-06-30 | $1.19 | $3.79 | x |
| 2016-06-30 | $-1.34 | $3.79 | x |
| 2017-06-30 | $-0.16 | $3.79 | x |
| 2018-06-30 | $-0.20 | $3.79 | x |
| 2019-06-30 | $-0.11 | $3.79 | x |
| 2020-06-30 | $0.13 | $3.79 | x |
| 2021-06-30 | $0.26 | $3.79 | x |
| 2022-06-30 | $3.63 | $3.79 | x |
| 2023-06-30 | $6.11 | $3.79 | x |
| 2024-06-30 | $2.08 | $3.79 | x |
| 2025-06-30 | $11.66 | $3.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Incannex Healthcare Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -350.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54517.44%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.53x
- Recent ROE (-350.18%) is below the historical average (-129.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -18.07% | 0.00% | 0.00x | 1.26x | $-376.60K |
| 2007 | -14.79% | 0.00% | 0.00x | 1.03x | $-1.65 Million |
| 2008 | -11.55% | 0.00% | 0.00x | 1.11x | $-2.05 Million |
| 2009 | -59.46% | 0.00% | 0.00x | 2.25x | $-4.57 Million |
| 2010 | 20.74% | 9667.34% | 0.00x | 1.31x | $1.32 Million |
| 2011 | -30.36% | 0.00% | 0.00x | 1.32x | $-6.15 Million |
| 2012 | -15.87% | -4757.45% | 0.00x | 1.20x | $-5.20 Million |
| 2013 | -98.62% | -37900.73% | 0.00x | 1.42x | $-14.72 Million |
| 2014 | -687.54% | 0.00% | 0.00x | 4.47x | $-12.14 Million |
| 2015 | -534.75% | 0.00% | 0.00x | 13.16x | $-2.61 Million |
| 2016 | 0.00% | -804.97% | 0.26x | 0.00x | $-649.90K |
| 2017 | 0.00% | -7336.22% | 0.28x | 0.00x | $-20.75 Million |
| 2018 | 0.00% | -291.24% | 1.42x | 0.00x | $-2.90 Million |
| 2019 | 0.00% | -230.67% | 2.27x | 0.00x | $-2.68 Million |
| 2020 | -214.21% | -776.62% | 0.21x | 1.34x | $-4.87 Million |
| 2021 | -126.69% | -430.07% | 0.27x | 1.09x | $-8.81 Million |
| 2022 | -41.40% | -1898.02% | 0.02x | 1.06x | $-18.50 Million |
| 2023 | -234.39% | -7246.01% | 0.03x | 1.14x | $-76.60 Million |
| 2024 | -164.56% | -153825.00% | 0.00x | 1.52x | $-19.58 Million |
| 2025 | -350.18% | -54517.44% | 0.00x | 1.53x | $-48.22 Million |
Industry Comparison
This section compares Incannex Healthcare Ltd ADR's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $234,733,134
- Average return on equity (ROE) among peers: -29.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Incannex Healthcare Ltd ADR (IXHL) | $75.23 Million | -18.07% | 0.07x | $38.01 Million |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $177.38 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $7.56 Million |
| Akebia Ther (AKBA) | $68.12 Million | -199.28% | 3.41x | $263.59 Million |
| Alkermes Plc (ALKS) | $1.04 Billion | -15.16% | 0.88x | $7.35 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $5.18 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $263.49 Million | 12.07% | 0.07x | $190.27 Million |
| ANI Pharmaceuticals Inc (ANIP) | $457.60 Million | 4.10% | 0.98x | $1.80 Billion |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more